The Diabetes Management - Basic panel is a fundamental tool designed to help monitor and manage diabetes effectively. This panel includes a series of tests that provide a comprehensive overview of a patient's metabolic status, blood glucose control, and kidney function. By assessing these key markers, healthcare providers can evaluate the current state of a patient's diabetes, identify potential complications early, and adjust treatment plans to ensure optimal management of the disease.

 The Diabetes Management - Advanced panel is an extensive diagnostic tool designed to provide a thorough evaluation of a patient’s diabetic status and associated health risks. This panel includes a comprehensive range of tests that assess blood glucose control, kidney function, lipid metabolism, insulin levels, and overall metabolic health. The combination of these tests offers a holistic view of a diabetic patient's condition, enabling healthcare providers to develop effective management and treatment plans.

 The Diabetes Management - Basic Plus panel is an enhanced diagnostic tool designed to provide a more comprehensive assessment of diabetes management compared to the basic panel. This panel includes tests that not only monitor blood glucose control and kidney function but also provide insights into blood health and lipid metabolism. By expanding the range of biomarkers assessed, this panel helps healthcare providers to better understand the overall health status of diabetic patients and to identify potential complications at an early stage.

 The Diabetes Management - Comprehensive panel is an extensive diagnostic tool designed to provide a thorough evaluation of a patient's diabetic status and associated health risks. This panel includes a broad range of tests that assess blood glucose control, kidney function, lipid metabolism, inflammation, and overall metabolic health. By offering a detailed picture of a diabetic patient's condition, healthcare providers can develop and refine effective management and treatment plans to optimize patient outcomes and prevent complications.

Comprehensive GLP-1 metabolic monitoring panel including Hemoglobin A1c, fasting glucose, insulin, lipid panel, hs-CRP, and full metabolic panel with liver enzymes, kidney markers, and electrolytes. Designed to support baseline assessment and ongoing monitoring of glycemic control, insulin resistance, cardiometabolic risk, and organ function during GLP-1–based therapy.

The Cardio IQ™ Diabetes Risk Panel with Score combines advanced biomarker analysis to evaluate insulin resistance, lipid metabolism, and glycemic control. This panel generates a diabetes risk score that helps identify individuals at increased risk for type 2 diabetes and related cardiometabolic complications. It provides insight into metabolic health, supporting early intervention, lifestyle planning, and long-term disease management.

The Hemoglobin A1c, Insulin, and Glucose Panel is a comprehensive test used to evaluate blood sugar control, insulin function, and potential glucose metabolism disorders. This panel is crucial for diagnosing and monitoring diabetes and pre-diabetes conditions.

The Insulin and Glucose panel is a focused diagnostic tool used to evaluate blood sugar levels and insulin, the hormone responsible for regulating glucose uptake from the bloodstream into the cells. This panel includes two essential tests: one for measuring glucose levels and another for assessing insulin levels in the blood. Together, these tests provide valuable insights into the body's glucose metabolism and insulin function, which are crucial for diagnosing and managing diabetes and other metabolic disorders.

 The Glutamic Acid Decarboxylase-65 (GAD-65), IA-2, and Insulin Autoantibodies Test is a diagnostic tool employed to assess autoantibodies directed against specific proteins involved in the regulation of insulin production. This test plays a crucial role in the identification and monitoring of autoimmune conditions, particularly Type 1 diabetes, as well as providing insights into the risk of developing diabetes in susceptible individuals.